zinet home
home home
home ИНТЕЛЛЕКТ-ПОРТАЛ
home Стартовал прием материалов в сборник XХХIX-й научной конференции. Требования к публикациям - в разделе "Объявления".

На главную | Объявления | Отчеты предыдущих конференций | История Украины | Контакты

РЕСУРСЫ ПОРТАЛА:

Тридцать восьмая научно-практическая конференция
(23 - 28 мая 2016 г.)


Тридцать седьмая научно-практическая конференция
(19 - 22 апреля 2016 г.)


Тридцать шестая научно-практическая конференция
(29 декабря 2015 - 5 января 2016 г.)


Тридцать пятая научно-практическая конференция
(24-27 ноября 2015 г.)


Тридцать четвертая научно-практическая конференция
(13-17 октября 2015 г.)


Тридцать третья научно-практическая конференция
(20-27 мая 2015 г.)


Тридцать вторая научно-практическая конференция
(2-7 апреля 2015 г.)


Тридцать первая научно-практическая конференция
(25 февраля - 1 марта 2015 г.)


Тридцатая научно-практическая конференция
(19-25 января 2015 г.)


Двадцать девятая международная научно-практическая конференция
(19-25 ноября 2014 г.)


Двадцать восьмая международная научно-практическая конференция
(08-13 октября 2014 г.)


Двадцать седьмая научно-практическая конференция
(20-25 мая 2014 г.)


Двадцать шестая научно-практическая конференция
(7-11 апреля 2014 г.)


Двадцать пятая юбилейная научно-практическая конференция
(3-7 марта 2014 г.)


Двадцать четвертая научно-практическая конференция
(20-25 января 2014 г.)


Двадцать третья научно-практическая конференция
(10-15 декабя 2013 г.)


Двадцать вторая научно-практическая конференция
(4-9 ноябя 2013 г.)


Первая международная научно-практическая конференция
(14-18 мая 2013 г.)


Двадцать первая научно-практическая конференция
(14-18 мая 2013 г.)


Двадцатая научно-практическая конференция
(20-28 апреля 2013 г.)


Девятнадцатая научно-практическая конференция
(26 февряля - 3 марта 2013 г.)


Восемнадцатая научно-практическая конференция
(22-26 декабря 2012 г.)


Семнадцатая научно-практическая конференция
(22-26 октября 2012 г.)


Шестнадцатая научно-практическая конференция
(09-14 апреля 2012 г.)


Пятнадцатая научно-практическая конференция
(01 - 07 марта 2012 г.)


Четырнадцатая научно-практическая конференция
(12-20 декабря 2011 г.)


Тринадцатая научно-практическая конференция
(28 октября - 09 ноября 2011 г.)


Двенадцатая научно-практическая конференция
(28 мая - 06 июня 2011 г.)


Одинадцатая научно-практическая конференция
(26 апреля - 04 мая 2011 г.)


Десятая научно-практическая конференция
(15-23 марта 2011 г.)


Девятая научно-практическая конференция
(27-31 декабря 2010 г.)


Восьмая научно-практическая конференция
(05-12 декабря 2010 г.)


Седьмая научно-практическая конференция
(28 мая - 7 июня 2010 г.)


Шестая научно-практическая конференция
(1-15 апреля 2010 г.)


Пятая научно-практическая конференция
(20-27 мая 2009 г.)


Четвертая научно-практическая конференция
(10-17 апреля 2009 г.)


Третья научно-практическая конференция
(20-27 декабря 2008 г.)


Вторая научно-практическая конференция
(1-7 ноября 2008 г.)


Первая научно-практическая конференция
(10-15 мая 2008 г.)



НАШИ ПАРТНЕРЫ:

Студия веб-дизайна www.zinet.info



Студия ландшафтного дизайна Флора-МК


Уникальное предложение!



Сайт-визитка - теперь
всего за 200 грн!

подробнее>>>



PSYCHOTROPIC ACTIVITY OF NEWLY SYNTHESIZED SALICYLATES AT VARIOUS DOSES

 

Cheretayev I.V., Yakovchyuk T.V., Koreniuk I.I.,

Khusainov D.R., Gamma T.V., Epishkin I.V.

Ukraine, Simferopol, Тaurida National I.I. Vernadsky University

 

Abstract: It is shown that psychotropic activity of newly synthesized salicylates at various doses is manifested as a nonmonotonic dependence having its peaks at therapeutic and ultra-low dose zones.

Key words: psychotropic activity, salicylates, therapeutic doses, ultra-low doses.

 

The effectiveness of most pharmaceutical products is noted to rise as the dose is increased, in some cases reaching its maximum at high dosage rate. However, the administration of pharmaceutical products at therapeutic doses and at high doses, a fortiori, is usually accompanied by the development of a broad spectrum of side-effects. Thus, for acetylsalicylic acid (Asp), along with the anti-inflammatory and analgesic action, the manifestation of psychotropic effects is observed at the upper limit of therapeutic dose (TD) [3]. Aspirin, in spite of having the great number of positive properties, also provokes stomach ulceration, negatively influences the cells of liver and of blood [1]. It should be noted that the spectrum of side-effects enlarges as the dose is increased. It was shown pharmacological activity of aspirin at ultra-low doses (ULD) with decreasing side-effects recently, and it was found anti-stress, anxiolytic, antidepressant effects at TD and ULD [7]. No exceptions, that newly synthesized aspirin's derivatives – acetylsalicylate cobalt (ASC) and acetylsalicylate zinc (ASZ), which manifested psychotropic activity at TD, is probable to preserve the same properties at ULD, but without side-effects. Due to the strictly individual nature of effect manifestation at ULD for each pharmaceutical product [2], this work is aimed to reveal the specificity of psychotropic effects of ASС and ASZ at various doses and to compare them with the action of aspirin.

The research was conducted at 250 white outbred male rats having 200-250 gr of weight that were divided into 25 groups, 10 animals in each group. The studied substances (Asp, acetylsalicylate cobalt (ASC) and acetylsalicylate zinc (ASZ)) were diluted in normal saline and injected intraperitoneally (i.p.) 0.2 ml at a time, at high doses (120 and 80 mg/kg), at TD (40, 15 mg/kg), “dead zone” dose (40·10-4 mg/kg) and at the three ULD (40·10-8, 40·10-10, 40·10-13 mg/kg). The animals of the control group were administered to the equivalent volume of normal saline solution. The TD and ULD zones are separated by the “dead zone” in dosage range 10-12-10-8 M where the psychotropic effects are absent (Table 1). The control point at 40·10-4 mg/kg is taken to provide better illustration.

 

Тable 1. The ratio of dose/concentration.

 

High doses

Therapeutic doses

Dead zone

Ultra-low doses

Doses, mg/kg

120

80

40

15

40·10-4

40·10-8

40·10-10

40·10-13

concentration

3·10-4

2·10-4

10-4

3,8·10-3

40·10-8

10-12

10-14

10-17

 

30 minutes after the i.p. injection we studied the behavioral response of the rats using open field test [8] and Porsolt’s test [9]. The reliability of disparity between the control group and the experimental group was estimated with the use of non-parametric U-criterion by Mann-Whitney (p ≤ 0,05, р ≤ 0,01). The data is represented in relative units (%), values of the control group being taken for 100%.

The standard Open Field test is commonly used to assess locomotor, exploratory and anxiety-like behavior in laboratory animals (rats/mice). This test is particularly useful in evaluating the effects of anxiolytic and anxiogenic drugs, locomotor responses to drug and as well as behavioral responses to novelty. The Open Field area generally consists of an empty and bright square arena, surrounded by walls to prevent animal from escaping.

The animal is usually place in the center of the arena and its behavior recorded for 3 min. We are registered horizontal motor activity and research activity.

Porsolt’s test is the most commonly used test for assessment of depressive status in animals. The experimental setup is a transparent cylinder filled with water of room temperature. A rat is placed in the water; its behavior is observed for 3 min. The time of active swimming and the time of immobility (when a rat just weakly moves the paws to keep afloat) are registered. The latter is interpreted as “hope loss behavior” and is longer in animals with depressive-like status. This immobility time is decreased by antidepressants.

The reliability of disparity between the control group and the experimental group was estimated with the use of nonparametric U-criterion by Mann-Whitney (p ≤ 0.05, р ≤ 0.01). The data is represented in relative units (%), values of the control group being taken for 100%. During the experiments all the ethic norms were observed.

The Figure 1, A shows psychotropic effects of Asp in dependence on the dose in the Open Field test. It is obvious that Asp at high doses significantly raised the horizontal movement activity (HMA) and investigative activity (IA) which is the evidence of its marked anti-stress and anxiolytic action (р ≤ 0.01) [8]. At the upper limit of TD of Asp (40 mg/kg) IA was decreased reliably and HMA—unreliably, that is, anxiogenic effect was produced instead of anxiolytic one, anti-stress action neutralized. At 40∙10–8 mg/kg Asp dose the effects of TD (40 mg/kg) were repeated. At 40∙10–10 and 40∙10–13 mg/kg the anxiogenic action of Asp became obsolete, but anti-stress action was revealed against this background.

 

Figure 1. The curves “dose-effect” of aspirin (A), acetylsalicylate zinc (B) and acetylsalicylate cobalt (C) in open field test.

 

ASZ at high doses, as well, as Asp, increased HMA and IA in the animals, which is the evidence of its anti-stress and anxiolytic action (Figure 1, B). The dose being decreased, ASZ shows the growth of its anxiolytic effect along with the reduction of anti-stress one. At the upper limit of TD (40 mg/kg) anxiolytic effect reaches its maximum, while anti-stress effect is not manifested at TD Zone at all. Further decrease of the dose causes neutralization of psychotropic effects of ASZ. However, at 40∙10–8 mg/kg dose ASZ makes anxiolytic action, but it is less marked than that one at TD. At other ULD (40∙10–10 and 40∙10–13 mg/kg) anti-stress action of ASZ is well seen in the absence of anxiolytic effect. ASC at high doses produced toxic effect. Under these conditions 70% of the sampling administered to 120 mg/kg dose, and 40% of the sampling administered to 80 mg/kg died. The surviving animals were excluded from further experiment. At the upper limit of TD anxiolytic action of ASC was manifested (Figure 1, C). The dose being decreased, the effect grew neutralized. At ULD Zone a certain regularity of effect development is discovered: the dose being decreased, anxiolytic action of ASC grows 2 times as much as that at TD, then at 40∙10–10 mg/kg dose the effect is ne utralized, to be manifested again at 40∙10–13 mg/kg dose, but with less intensity. It must be noted that anxiolytic effect of ASC at ULD is accompanied by anti-stress effect development, reaching its maximum at 40∙10–13 mg/kg dose.

Thus, judging by the results of the Open Field test we can see that the same way of psychotropic effects development is typical for both Asp and ASC. It must be noted that ASC has the most intensive anxiolytic action at ULD Zone (40∙10–13 mg/kg) compared with Asp and ASC, where substances preserve their biologically active properties, but side-effects are absent.

At Figure 2, A we can see that in Porsolt test Asp at all doses extended the time of active swimming and reduced the time of immobility in experimental group rats as compared with the control group animals (р ≤ 0,05), which is the evidence of its antidepressant action [3]. At 120 mg/kg dose Asp demonstrated development of the maximum antidepressant effect that decreased at TD (40 mg/kg). The dose being decreased, antidepressant effect was neutralized, to be manifested again at ULD Zone, repeating the TD effect.

ASZ at high doses showed antidepressant action. At the upper limit of TD it was reduced insignificantly (Figure 2, B). The decrease of the dose caused neutralization of the effect. At ULD Zone ASZ at 40∙10–8 mg/kg dose significantly raised the depression level in animals, which was manifested by reduction of active swimming time and, correspondingly, extension of immobility time. However, at 40∙10–10 and 40∙10–13 mg/kg ASZ demonstrated antidepressant effect. This fact indicates the inversion of substance operational sign at 40∙10–8 mg/kg dose. ASC at the upper limit of TD had antidepressant action. The dose brought down to 15 mg/kg, this effect was neutralized, the same way as at the dead zone (Figure 2, C). At ULD Zone, all doses of ASC extended the time of active swimming and, correspondingly, reduced the time of immobility. This is the evidence of antidepressant effect of ASC at ULD. Consequently, of all the studied substances maximum antidepressant effect at ULD was demonstrated by ASC, compared with Asp and ASZ.

 

Figure 2. The curves “dose-effect” of aspirin (A), acetylsalicylate zinc (B) and acetylsalicylate cobalt (C) in Porsolt’s test.

 

Thus, we have shown that in case of salicylates administration at various doses their psychotropic action is manifested as a nonmonotonic dependence having its peaks at both TD and ULD zones. It must be noted that the development of psychotropic effect at ULD is accompanied by manifestation of the new properties. On summing up the data we discovered that ASC, causing acute toxicity at high doses, resulted in maximum intensity effects of all the tested compounds when used at ULD.

Generally, we have shown that administration of Asp and its salts at high doses causes maximum psychotropic effects to occur. However, the use of both Asp and its derivatives [5] at the studied dosage range is often accompanied by side-effects; moreover, for ASC at high doses the acute toxicity and, consequently, lethality is typical. So, the high doses of Asp must be administered with caution, while its newly synthesized derivatives require to be carefully studied as to having biological effectiveness at lower doses.

According to the results of this research, ULD zone has shown psychotropic action which repeats the effects of high doses and TD, at that approaching the maximum intensity at the lowest doses. The use of Asp at ULD offers a number of advantages: e.g., no side effects, a more pronounced effectiveness compared with TD, etc. The results give us grounds for recommending the use of Asp at ULD in clinical testing as a psychotropic medication.

The absence of biological effects of Asp and its salts at 10–12-10–8 range is explained by the “dead zone” existence. This phenomenon has been demonstrated in almost all experimental works. Formation of the “dead zone” is explained in literature by the hypothesis about the existence of the systems with negative feedback [10].

The material collected in the field of ULD study prevents us from skepticism towards ULD effects of biologically active substances, and, undoubtedly, the phenomenon of ULD is worth serious scientific studying.

The presence of psychotropic effects of Asp and its salts at ULD range has its prerequisites justified by the data from the literature on the subject. Asp at low doses has indicated effectiveness in treatment of the vascular heart diseases, prevention of Alzheimer disease. Also, scientists have conducted a complex research on blood coagulability under aspirin influence at various doses [3]. First they studied the effects of the medication at therapeutic doses, after that – at low doses, then – to extremely low ones, and finally – to apparent concentrations. At that, they discovered an interesting phenomenon while studying the role of aspirin in blood clotting. The scientists decided to test the effectiveness of the medication made “after Hahnemann”, that is, as a homeopathic preparation. It was found that “ultra-low-dose aspirin” (ULDA-H) created antithrombotic effect by the mechanism other than that one at TD. While aspirin at TD knock out cyclooxygenase (COX-1), ULDA-H does not produce any effect on that, but it arrests COX-2. It is possible that Asp at ULD influences COX-2 getting to brain through hematoencephalic barrier. Moreover, it was shown that it is in brain where COX-2 is mainly contained, so it is only possible for non-steroidal anti-inflammatory drugs to reach anti-inflammatory effect in absence of side-effects on gastrointestinal tract and other tissues involved in COX-1 activity if they inhibit COX-2 activity electively [6].

However, no theory has been formulated yet in literature to explain to the fullest all the effects of extremely low doses of biologically active substances. Some efforts have been made to explain the observed effects by following hypotheses: concoction of the medical substance, existence of highly effective systems of receptor signaling transduction and enhancement, “adaptation” of receptors towards the action of extremely low doses, existence of supra-high-affinity receptors [4]. Also, it must be borne in mind that highly diluted solutions of Asp and its salts were prepared not by usual diluting method, but by the homeopathic potentiating method. Still, within the frame of this experiment the dosing frequency and the duration of salicylates treatment were not taken into consideration depending on the potency and dose.

Thus, there are a number of advantages in use derivatives of Asp at ULD in mental illnesses treatment. Upon that, the research has a perspective of further analyzing distinctive features of course treatment with aspirin’s salts and studying possible mechanisms of their action.

 

References:

1.     Alekseyeva L.I. Questions of use of non-steroidal anti-inflammatory drugs in rheumatology practice // Consilium Medicum Ukraina. – 2009. – № 4. – P. 3-7.

2.     Ashmarin I.P., Karazeyeva Y.P., Lelekova T.V. On the question of development of the problem of effectiveness extremely low doses of biologically active compounds // Rus. J. Chem. – 1999. – V. 43, № 5. – P. 21-27.

3.     C. Doutremepuich, O. Aguejouf, V. Desplat [et al.]. Aspirin therapy // Thrombosis and Haemostasis. – 2010. – V. 103, № 1. – P. 171-180.

4.     Burlakova Y.B., Kondratov A.A., Khudyakov I.V. Exposure to chemical agents at very small doses on biological objects // Bull. Acad. Sci. USSR. – 1990. – № 2. – P. 183-194.

5.     T.V. Yakovchyuk, O.V. Katyushyna, D.R. Husainov [et al.]. Influence of acetylsalicylic acid, cobalt and zinc aspirinates on rat behavior // Scientific Notes of Taurida National V. I. Vernadsky University. Biology, Chemistry. – 2010. – V. 23 (62), № 2. – P. 200-208.

6.     C. Brenneis, T. J. Maier, R. Schmidt [et al.]. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition // FASEB J. – 2006. – V. 20, № 9. – P. 1352-1360.

7.     Katiushina O.V., Koreniuk I.I., Khusainov D.R. Neuro- and psychotropic effects of acetylsalicylic asid and its salts – S.: LAP Lambert Academic Publishing, 2012. 72 p.

8.     Markel A.L. To evaluation of general characteristics of rat behavior in the open field test // J. High. Nerv. Act. – 1981. – V. 31, № 4. – P. 301-307.

9.     Porsolt R.D., Le Pinchon M., Jalfre M. Depression: A new animal model sensitive to antidepressant treatments // Nature. – 1977. – Vol. 266, № 5604. – P. 730-732.

10.  Sazanov L.A., Zaitsev S.V. Effect of superlow doses (10-18-10-16 М) of biologically active substances: General trends, salient features, and possible mechanisms // Biochemistry. – 1992. – V. 57, № 10. – P. 1443-1460.

11.  Zhang J.J., Ding E.L., Song Y.Q. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events // Clinician’s Corner. – 2006. – V. 296, № 13. – P. 1619-1632.



Первая научно-практическая конференция
"Инновационный потенциал украинской науки - ХХI век"
(10-15 мая 2008 г.)


(отчет)
Вторая научно-практическая конференция
"Инновационный потенциал украинской науки - ХХI век"
(1-7 ноября 2008 г.)
(отчет)
Третья научно-практическая конференция
"Инновационный потенциал украинской науки - ХХI век"
(20-27 декабря 2008 г.)
(отчет)
Четвертая научно-практическая конференция
(10-17 апреля 2009 г.)
(отчет)
Пятая научно-практическая конференция
(20-27 мая 2009 г.)
(отчет)
Шестая научно-практическая конференция
(1-15 апреля 2010 г.)
(отчет)
Седьмая научно-практическая конференция
(28 мая - 7 июня 2010 г.)
(отчет)
Восьмая научно-практическая конференция
(05-12 декабря 2010 г.)
(отчет)
Девятая научно-практическая конференция
(27-31 декабря 2010 г.)
(отчет)
Десятая научно-практическая конференция
(15-23 марта 2011 г.)
(отчет)
Одинадцатая научно-практическая конференция
(26 апреля 04 мая 2011 г.)
(отчет)
Двенадцатая научно-практическая конференция
(28 мая - 06 июня 2011 г.)
(отчет)
Тринадцатая научно-практическая конференция
(28 октября - 09 ноября 2011 г.)
(отчет)
Четырнадцатая научно-практическая конференция
(12-20 декабря 2011 г.)
(отчет)
Пятнадцатая научно-практическая конференция
(01-07 марта 2012 г.)
(отчет)
Шестнадцатая научно-практическая конференция
(09-14 апреля 2012 г.)
(отчет)
Семнадцатая научно-практическая конференция
(22-26 октября 2012 г.)
(отчет)
Восемнадцатая научно-практическая конференция
(22-26 декабря 2012 г.)
(отчет)
Девятнадцатая научно-практическая конференция
(26 февраля - 3 марта 2013 г.)
(отчет)
Двадцатая научно-практическая конференция
(20-28 апреля 2013 г.)
(отчет)
Двадцать первая научно-практическая конференция
(13-18 мая 2013 г.)
(отчет)
Первая международная научно-практическая конференция
"Перспективные направления отечественной науки - ХХI век"
(13-18 мая 2013 г.)
(отчет)
Двадцать вторая научно-практическая конференция
(4-9 ноября 2013 г.)
(отчет)
Двадцать третья научно-практическая конференция
(10-15 декабря 2013 г.)
(отчет)
Двадцать четвертая научно-практическая конференция
(20-25 января 2014 г.)
(отчет)
Двадцать пятая юбилейная научно-практическая конференция
(3-7 марта 2014 г.)
(отчет)
Двадцать шестая научно-практическая конференция
(7-11 апреля 2014 г.)
(отчет)
Двадцать седьмая научно-практическая конференция
(20-25 мая 2014 г.)
(отчет)
Двадцать восьмая научно-практическая конференция
(08-13 октября 2014 г.)
(отчет)
Двадцать девятая научно-практическая конференция"
(19-25 ноября 2014 г.)
(отчет)
Тридцатая научно-практическая конференция
(19-25 января 2015 г.)
(отчет)
Тридцать первая научно-практическая конференция
(25 февраля - 1 марта 2015 г.)
(отчет)
Тридцать вторая научно-практическая конференция
(2 - 7 апреля 2015 г.)
(отчет)
Тридцать третья научно-практическая конференция
(20 - 27 мая 2015 г.)
(отчет)
Тридцать четвертая научно-практическая конференция
(13 - 17 октября 2015 г.)
(отчет)
Тридцать пятая научно-практическая конференция
(24 - 27 ноября 2015 г.)
(отчет)
Тридцать шестая научно-практическая конференция
(29 декабря 2015 - 5 января 2016 г.)
(отчет)
Тридцать седьмая научно-практическая конференция
(19 - 22 апреля 2016 г.)
(отчет)
Тридцать восьмая научно-практическая конференция
(23 - 25 мая 2016 г.)
(отчет)

На главную | Объявления | Отчеты предыдущих конференций | История Украины | Контакты

Copyright © Zinet.info. Разработка и поддержка сайта - Студия веб-дизайна Zinet.info